에 대한 최신 뉴스 Novanta (NASDAQ:NOVT) 주식

Novanta

Novanta Inc manufactures photonic and motion-control components for original equipment manufacturers in the medical equipment and industrial technology markets. The firm operates in three segments: Precision Medicine and Manufacturing, Medical Solutions, and Robotics and Automation. It generates the majority of its revenue from the Medical Solutions segment that designs, manufactures, and markets a range of medical-grade technologies, including medical insufflators, pumps, and related disposables; visualization solutions; and wireless technologies. The firm generates the majority of its revenue from the United States and Europe.

Novanta Inc

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

BJDX

SMST

LIFW

SMCX

LIFWW

Numinus Wellness Inc. (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/NUMIF#OTCQX">NUMIF</a>), a leader in <a href="https://www.benzinga.com/topic/psychedelic-assisted-therapies">psychedelic-assisted mental health care</a>, has <a href="https://www.investors.numinus.com/news/news-details/2024/Numinus-Wellness-Announces-Sale-of-Clinics-and-Unique-Data-Partnership-to-Increase-Access-to-Mental-Health-Care/default.aspx">announced</a> a definitive agreement with Stella, an interventional psychiatry practice, to sell its five wellness clinics in Utah for a total of $3.53 million. The transaction, expected to close by November 30, marks a strategic shift for Numinus, as it pivots towards <a href="https://www.benzinga.com/markets/cannabis/24/09/40845569/mdma-therapy-for-ptsd-faces-fda-delay-are-there-other-ways-forward">developing technology-driven solutions</a> aimed at enhancing the efficiency of mental health care providers.
<h3 class="wp-block-heading">Tech Partnership To Redefine Mental Health Clinics</h3>
In addition to the sale, Numinus and Stella will collaborate on a data-sharing initiative to launch an innovative clinic management platform. By leveraging operational insights from Stella's 12 clinics, Numinus plans to develop a software solution designed to streamline clinic operations, enhance patient outcomes and support insurance reimbursement processes.
"This transaction marks an exciting new chapter in Numinus' strategy to reshape behavioral health care," said Payton Nyquvest, founder and CEO of Numinus. "Leveraging our expertise in patient care, we're now accelerating our mission by focusing on cutting-edge technology solutions. Through our partnership with Stella, we gain unprecedented access to operational data that will enable us to develop a SaaS (software as a service) solution to redefine how clinics operate."
<h3 class="wp-block-heading">Stella Takes Over Utah Operations</h3>
Stella, known for its focus on treating PTSD, anxiety and depression through biological modalities, will assume control of Numinus' Utah clinics. The acquisition includes an upfront payment of $2.08 million, followed by $750,000 in installments throughout 2025, and up to $700,000 in deferred compensation.
"Stella's expansion into Utah brings additional life-changing treatments to the community while supporting Numinus' broader tech initiatives," stated Michael Gershenzon, co-founder and CEO of Stella. "This partnership reflects our commitment to improving behavioral health systems and processes, ultimately enhancing patient care."
<h3 class="wp-block-heading">An Asset-Light Business Model With Enhanced Focus</h3>
With the sale of its clinics, Numinus will shift towards an asset-light model, focusing on its business units like Cedar Clinical Research and the Numinus Network. The strategy aims to integrate clinical research, practitioner training and technology solutions, supporting mental health providers worldwide. The move is part of a broader effort to ease the operational burdens faced by healthcare professionals, particularly as demand for treatments like <a href="https://www.benzinga.com/topic/ketamine-therapy">ketamine</a> and Spravato continues to rise.
"Stella will bolster our clinical solutions offering, leveraging their deep expertise in patient care," Nyquvest added. "We expect strong demand for our Numinus Network Solutions as mental health practitioners navigate growing requests for care."
Cover image made with AI

Cannabis

News

Psychedelics

NUMIF

Numinus Wellness Sells US Clinics, Partners With Stella For Tech-Driven Mental Health Solutions

President-elect Donald Trump has chosen former Representative Doug Collins (R-GA) to lead the <a href="https://www.benzinga.com/cannabis">U.S. Department of Veterans Affairs (VA). </a>
The decision has sparked discussions about how the agency might handle medical cannabis issues, given his inconsistent track record on the issue, as <a href="https://www.marijuanamoment.net/trumps-pick-to-lead-va-voted-against-letting-agency-doctors-recommend-medical-marijuana-to-veterans-before-he-adopted-a-pro-reform-position/">reported</a> Marijuana Moment.
<h3 class="wp-block-heading">Collins' Record On Cannabis</h3>
During his time in Congress, Collins opposed efforts to expand access to medical cannabis for veterans. Between 2014 and 2016, he voted against three proposals that would have allowed VA doctors to recommend cannabis to their patients.
See Also: <a href="https://www.benzinga.com/markets/cannabis/24/11/42018478/trumps-cabinet-choices-will-his-administration-support-or-restrict-cannabis">Trump&#8217;s Cabinet Choices: Will His Administration Support Or Restrict Cannabis?</a>
Collins' views began to shift in 2019. He supported the STATES Act, which would protect state marijuana programs from federal interference, and co-signed a letter with Rep. Matt Gaetz (R-FL), urging Congress to take action on cannabis policy. 
"We believe this Committee and this Congress must act to clarify the rights and responsibilities, relative to cannabis, of individuals, physicians, businesses, medical patients, and law enforcement officials," they wrote.
Later that year, Collins backed a bipartisan bill to protect banks that serve marijuana businesses in states where it is legal. However, he did not take part in a 2020 vote on federal cannabis legalization.
<h3 class="wp-block-heading">Collins' Stance On Psychedelics</h3>
When it comes to psychedelics, there isn't much known about Collins's stance. However, his shifting views on cannabis policy hint that he could be open to exploring different approaches.
<h3 class="wp-block-heading">Cannabis At The VA</h3>
VA policy has long prohibited its doctors from recommending cannabis, citing marijuana's classification as a Schedule I controlled substance under federal law. This stance has remained consistent across both Republican and Democratic administrations, despite growing support for change in Congress.
Recent efforts to address this issue include a Senate Appropriations Committee request for the VA to explore cannabis as an alternative to opioids. Lawmakers have also introduced measures that would allow VA doctors to recommend cannabis in states where it is legal. These efforts have gained bipartisan support, but none have yet become law.
Veterans service organizations have pushed for further reforms, including expanded research into the potential benefits of cannabis. Last year, a Senate committee approved a bill to study cannabis for veterans with certain medical conditions, but it failed to advance to a floor vote.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/24/11/42017583/trumps-go-wild-on-health-plan-puts-rfk-jr-in-charge-what-it-means-for-cannabis-and-psychedelics-reform">Trump&#8217;s &#8216;Go Wild On Health&#8217; Plan Puts RFK Jr. In Charge: What It Means For Cannabis And Psychedelics Reform</a></li>
</ul>
Cover image made with AI.

Government

Politics

Markets

Trump-Appointed Doug Collins To Lead VA: What's Next For Cannabis and Psychedelics In Veterans' Healthcare?

Chardan Capital analyst Daniil Gataulin maintains Clearside Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) with a Buy and maintains $6 price target.

Price Target

Analyst Ratings

CLSD

Chardan Capital Maintains Buy on Clearside Biomedical, Maintains $6 Price Target

Chardan Capital analyst Daniil Gataulin maintains Cognition Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) with a Buy and maintains $11 price target.

CGTX

Chardan Capital Maintains Buy on Cognition Therapeutics, Maintains $11 Price Target

Telsey Advisory Group analyst Cristina Fernandez maintains Williams-Sonoma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) with a Outperform and maintains $165 price target.

Telsey Advisory Group Maintains Outperform on Williams-Sonoma, Maintains $165 Price Target

– Approval based on positive data from the AUGMENT-101 clinical trial, in which Revuforj delivered robust and durable rates of remission in R/R acute leukemia patients with a KMT2A translocation –
– Syndax to host conference call today at 6:00 p.m. ET –
WALTHAM, Mass., Nov. 15, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) today announced that the U.S. Food and Drug Administration (FDA) has approved Revuforj&#xAE; (revumenib) as the first and only menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients one year and older. The FDA previously granted Breakthrough Therapy and Fast Track designations as well as Priority Review for Revuforj. The New Drug Application (NDA) received approval through the FDA's Real Time Oncology Review (RTOR) program.

Biotech

General

SNDX

Syndax Announces FDA Approval Of Revuforj, The First And Only Menin Inhibitor To Treat Adult And Pediatric Patients With Relapsed Or Refractory Acute Leukemia With A KMT2A Translocation

IT Tech Packaging (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ITP#AMEX">ITP</a>) reported quarterly losses of $(0.20) per share. This is unchanged from the same period last year. The company reported $25.08 million in sales this quarter. This is a 59.03 percent increase over sales of $15.77 million the same period last year.

Earnings

IT Tech Packaging Q3 EPS $(0.20), Same YoY, Sales $25.08M Up From $15.77M YoY

RumbleOn, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMBL#NASDAQ">RMBL</a>) (the "Company" or "RumbleOn") announced today that the close of business (4:00 p.m. Central Time) on November 25, 2024 has been fixed as the record date (the "Record Date") for its previously announced proposed $10.0 million registered equity rights offering (the "Rights Offering"), which was announced in a Form 8-K filed with the U.S. Securities and Exchange Commission ("SEC") on November 12, 2024.

Offerings

RMBL

RumbleOn Announces That The Close Of Business On November 25, 2024 Has Been Fixed As The Record Date For Its Previously Announced Proposed $10M Registered Equity Rights Offering

Telsey Advisory Group analyst Dana Telsey maintains European Wax Center (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWCZ#NASDAQ">EWCZ</a>) with a Outperform and maintains $8 price target.

EWCZ

Telsey Advisory Group Maintains Outperform on European Wax Center, Maintains $8 Price Target

<a href="https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241115-1475367/1475367_4rcm.pdf" title="https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241115-1475367/1475367_4rcm.pdf">https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241115-1475367/1475367_4rcm.pdf</a>

FOUR

Shift4 Payments Will Replace R1 RCM In The S&P Midcap 400 Effective Prior To The Opening Of Trading On Wednesday, November 20

China Green Agriculture, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CGA#NYSE">CGA</a>) has changed its name to Enlightify Inc., effective November 25, 2024. Its ticker symbol will change to ENFY effective November 25, 2024, and it is expected to begin trading under that symbol on November 26, 2024. The Company mainly produces and distributes humic acid-based compound fertilizers, other varieties of compound fertilizers and agricultural products through its subsidiaries in China.

China Green Agriculture Changes Name to Enlightify Inc.; Its Ticker Symbol Will Change To 'ENFY' Effective November 25, 2024, And It Is Expected To Begin Trading Under That Symbol On November 26, 2024

Alpha Cognition (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACOG#NASDAQ">ACOG</a>) reported quarterly losses of $(0.31) per share. This is a 63.1 percent increase over losses of $(0.84) per share from the same period last year.

ACOG

Alpha Cognition Q2 EPS $(0.31) Up From $(0.84) YoY

D. Boral Capital analyst Jason Kolbert maintains NRX Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) with a Buy and maintains $31 price target.

NRXP

D. Boral Capital Maintains Buy on NRX Pharmaceuticals, Maintains $31 Price Target

D. Boral Capital analyst Jason Kolbert maintains VolitionRX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VNRX#AMEX">VNRX</a>) with a Buy and maintains $5 price target.

VNRX

D. Boral Capital Maintains Buy on VolitionRX, Maintains $5 Price Target

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Novanta (NASDAQ:<a href="https://investorplace.com/stock-quotes/novt-stock-quote/">NOVT</a>) just reported results for the second quarter of 2024.<ul><li>Novanta reported earnings per share of 73 cents. This was above the analyst estimate for EPS of 69 cents.</li><li>The company reported revenue of $235.86 million.</li><li>This was 0.96% better than the analyst estimate for revenue of $233.61 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/novt-stock-earnings-novanta-for-q2-of-2024/">NOVT Stock Earnings: Novanta Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

NOVT Stock Earnings: Novanta Beats EPS, Beats Revenue for Q2 2024

Novanta Inc. (NOVT) Q2 2024 Earnings Call Transcript

Novanta (NOVT) has released an update. Novanta Inc., a company registered in New Brunswick, Canada, has filed a Form 8-K with the SEC, indicating a...

Novanta Files Form 8-K With SEC, Reveals Key Updates

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
I am fascinated by robots. From an investment standpoint, robotics looks to be the natural complement to AI&rsquo;s advancement. Capable machinery powered by the latest artificial intelligence platform can help businesses perform complex mechanical tasks in manufacturing, healthcare, and other sectors, cutting down process times and increasing efficiency to its maximum. Autonomous mobile robots (AMRs) are already popular in some sectors, so this might be a good time for other investors to shop around for robotics stocks to buy and hold.&nbsp;



Of course, you wouldn&rsquo;t want to buy just any old company, which is why I&rsquo;ll screen the market for the best robotics stocks to buy, gauging them on their fundamentals and capacity for longevity. Remember, robotics is not a new industry, but recent advances in AI make it an increasingly attractive investment area.



To get my list, I screened companies that operate in the robotics industry or have robotics-related business segments using the following criteria:



<ul><li>Debt-to-equity ratio: 1.25 and below. The debt-to-equity ratio measures a company&rsquo;s financial leverage. The lower the leverage ratio, the better it manages its obligations,</li>



<li>Return-on-equity ratio: 15% and above. Return on equity measures how efficiently the company handles its capital to produce profits. Fifteen percent is considered a good level, so I scanned for companies with higher than that,</li>



<li>Analyst rating: Buy or higher.</li>
</ul>I then sorted the list based on the highest to lowest ROE. Here are the results:



<h2>Teradyne (TER)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/07/teradyne-ter-1600-300x169.jpg" alt="Teradyne Silicon Valley office"><div>Source: Michael Vi / Shutterstock.com</div></div>Teradyne (NASDAQ:<a href="https://investorplace.com/stock-quotes/ter-stock-quote/">TER</a>) is the go-to name for automated test equipment used in industrial applications. The company&rsquo;s core business specializes in the semiconductor market. Besides its testing expertise, the company offers other services like automation and robotics.



Teradyne recently appointed <a href="https://investors.teradyne.com/news/teradyne-robotics-welcomes-james-davidson-as-chief-ai-officer/47a6ac9d-8517-448f-a2f2-507541cbbaf4">James Davidson as its Chief AI Officer</a>, aiming to support its vision to revolutionize the manufacturing industry by leveraging Davidson&rsquo;s experience in both robotics and artificial intelligence. In addition, Teradyne has partnered with the AI powerhouse Nvidia (NASDAQ:<a href="https://investorplace.com/stock-quotes/nvda-stock-quote/">NVDA</a>) to support the <a href="https://investors.teradyne.com/news/teradyne-robotics-to-bring-the-power-of-ai-to-robotics-with-nvidia/f89e3bc0-1345-4627-9349-569db0a6b88d">development of its automation capabilities</a>.



While Teradyne may have had a slower FY 2023 due to its revenue decline, its Robotics segment boasted <a href="https://investors.teradyne.com/news/teradyne-reports-fourth-quarter-and-fiscal-year-2023-results/cdd55ba1-4dfe-413e-9c53-53b39875a928">50% year-over-year growth in Q4 2023</a>, highlighting its strong potential for a growing market segment.&nbsp;



In addition, revenue in Q2 2024 was up <a href="https://investors.teradyne.com/news/teradyne-reports-second-quarter-2024-results/bc78c615-ddd9-4528-bf2d-44056c36f186">7% </a><a href="https://investors.teradyne.com/news/teradyne-reports-second-quarter-2024-results/bc78c615-ddd9-4528-bf2d-44056c36f186" target="_blank">year over year</a>, surpassing its guidance. CEO Greg Smith emphasized its robotics sector, and the growing demand for AI has been a strong catalyst in its growth. With an ROE of 18.77% and an almost non-existent debt-to-equity ratio, the company boasts a strong proposition for long-term investors looking for robotics stocks to buy and hold. Even Wall Street&rsquo;s <a href="https://www.nasdaq.com/market-activity/stocks/ter/analyst-research">strong buy</a> consensus agrees with this.&nbsp;



<h2>ESAB Corporation (ESAB)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/10/robotics-stocks-ai-1600-300x169.jpg" alt="a robot built in the essence of a human raising its hand to its chin implying deep thought. future tech stocks. AI stocks"><div>Source: Phonlamai Photo / Shutterstock.com</div></div>ESAB Corporation (NYSE:<a href="https://investorplace.com/stock-quotes/esab-stock-quote/">ESAB</a>), the world leader in cutting, fabrication, and welding equipment, offers various industrial solutions to its customers, including robotics, gas control equipment, and digital solutions. The company operates in two main segments:



<ul><li>EMEA &amp; APAC: Focuses on operations in Europe, India, Africa, the Middle East, and Asia Pacific,</li>



<li>Americas: Focuses on its North and South American operations.</li>
</ul>ESAB has been experiencing <a href="https://finance.yahoo.com/quote/ESAB/financials/">moderate yet continuous revenue growth</a> for several years. While earnings growth over the last three years has been flat, the company maintains a return on equity (ROE) of 17.49%. Its debt-to-equity ratio also stands at 0.59, demonstrating its effectiveness in managing debt.



In addition, <a href="https://esabcorporation.com/newsroom/esab-corporation-announces-fourth-quarter-2023-results-and-initiates-full-year-2024-guidance/">President and CEO Shyam P. Kambeyanda</a> has highlighted that the company&rsquo;s drivers for growth and profitability come from its new innovative products and EBX initiatives. No wonder it boasts a <a href="https://www.nasdaq.com/market-activity/stocks/esab/analyst-research">strong buy</a> consensus rating among nine analysts. With its strong commitment to growth and cash flow generation, it is a no-brainer to check out ESAB if you want to buy and hold robotics stocks.



<h2>Novanta (NOVT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/06/stocks-to-buy-button-keyboard-1600-300x169.jpg" alt='Blue "buy now" button on a keyboard with finger pressing down on it. French Election Stock Picks'><div>Source: shutterstock.com/Odua Images</div></div>When it comes to robotics discussions, some might already know Novanta (NASDAQ:<a href="https://investorplace.com/stock-quotes/novt-stock-quote/">NOVT</a>) due to its reputation in electronics, metrology, robotics, and automation. The company operates in three main segments:



<ul><li>Precision Medicine and Manufacturing: laser technology and optical engine products,</li>



<li>Medical Solutions: medical-grade technologies and visualization solutions,</li>



<li>Robotics and Automation: optical and inductive encoders, servo drives, precision motors, intelligent robotic end-of-arm technology solutions, etc.</li>
</ul>Novanta had a strong FY 2023, reaching a record revenue of <a href="https://investors.novanta.com/news/news-details/2024/Novanta-Announces-Financial-Results-for-the-Fourth-Quarter-and-Full-Year-2023/default.aspx">$882 million</a>, a 2.4% improvement over the previous year&rsquo;s $861 million. However, its earnings per share decreased slightly from $2.06 to $2.02, due mostly to acquisitions.&nbsp;



&ldquo;Combined with continuing to institutionalize the Novanta Growth System deep into our Company&rsquo;s culture,&rdquo; said CEO and chair Matthijs Glastra, &ldquo;our playbook will continue to deliver predictable, consistent, long-term growth and shareholder value.&rdquo;



Novanta&rsquo;s debt-to-equity ratio is currently 0.75, and its return-to-equity ratio is 16.58%, highlighting its strong financial foundation and effective management. Wall Street consensus currently rates NOVT stock as <a href="https://www.nasdaq.com/market-activity/stocks/novt/analyst-research">a&nbsp;consensus buy</a>. With its diverse product lineup and sound financials, Novanta is a strong contender for the best robotics stocks to buy today.



On the date of publication, Rick Orford did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines</a>.



On the date of publication, the responsible editor did not have (either directly or indirectly) and positions in the securities mentioned in this article.
<div>Rick Orford is a Wall Street Journal best-selling author, investor, influencer, and mentor. His work has appeared in the most authoritative publications, including Good Morning America, Washington Post, Yahoo Finance, MSN, Business Insider, NBC, FOX, CBS, and ABC News.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>
The post <a href="https://investorplace.com/2024/08/3-robotics-stocks-to-buy-and-hold-for-the-potential-of-huge-returns/">3 Robotics Stocks to Buy and Hold for the Potential of Huge Returns</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

3 Robotics Stocks to Buy and Hold for the Potential of Huge Returns

Novanta (NOVT) has shared an update. John Burke has been promoted to Chief Accounting Officer of Novanta Inc., taking over from Peter Chang who wil...

Novanta Promotes John Burke to Chief Accounting Officer

Novanta Inc.: Overpriced In A Weak Demand Market. Here's Why It's A Hold

Conestoga Capital Advisors Q3 2024 Quarterly Commentary

Novanta Non-GAAP EPS of $0.85 in-line, revenue of $244M beats by $1.67M

Novanta Inc. (NOVT) Q3 2024 Earnings Call Transcript

Novanta ( ($NOVT) ) has released its Q3 earnings. Here is a breakdown of the information Novanta presented to its investors. Novanta Inc., listed o...

Novanta Reports Q3 2024 Earnings and Future Growth

AAON

ALTR

ANSS

AXON

BLFS

BWMN

CGNX

COCO

CPRT

CSGP

CSWI

CWST

DSGX

ERII

ESAB

EXPO

FIVN

FOXF

FTNT

GWRE

HLMN

IDXX

IRMD

MAMA

MNESP

NOVT

OFLX

PCOR

PLMR

POOL

QTWO

RGEN

ROAD

SITE

SNPS

SPSC

TCYSF

TECH

THBRF

TKNO

TREX

TRNS

USPH

VCEL

VRSK

WLDN

Press Releases

Novanta Announces Financial Results for the First Quarter 2024

Novanta to Present at the CJS Securities 24th Annual New Ideas Summer Conference on Wednesday, July 10, 2024

Politan Details Why a Truly Independent Board is Urgently Needed at Masimo in Order to Protect Shareholder Value and Realize the Company's Full Potential

Novanta Inc. Schedules Earnings Release and Conference Call for Tuesday, August 6, 2024

Novanta to Present at Baird's 2024 Global Healthcare Conference on Tuesday, September 10, 2024

Novanta Announces Financial Results for the Second Quarter 2024

Politan Provides Update on Why Masimo Shareholders Should Support Urgently Needed Board Change at Company's 2024 AGM

Novanta Inc. Schedules Earnings Release and Conference Call for Tuesday, November 5, 2024

Novanta to Present at the Baird 2024 Global Industrial Conference on Wednesday, November 13, 2024

Comments

Novanta

뉴스

에 대한 최신 뉴스 Novanta (NASDAQ:NOVT) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌